US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Arin Tactical Tail Risk ETF

95.15

-0.1693-0.18%

Post-market: 95.150.00000.00%16:10 EDT

Volume:2K

Turnover:222.51K

Market Cap:111.24M

PE:- -

High:95.19

Open:95.17

Low:95.15

Close:95.32

52wk High:95.59

52wk Low:45.10

Shares:1.17M

Float Shares:1.17M

Volume Ratio:1.88

T/O Rate:0.20%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure

Simply Wall St.

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

DKSH Partners with BridgeBio to Distribute ATTR-CM Drug in Key Asia-Pacific Markets

AstraZeneca Advances Dual ATTR-CM Therapy With New Phase IIb Trial

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

AstraZeneca Targets Early Detection in China With New ATTR Heart Disease Study

Assessing BridgeBio Pharma (BBIO) Valuation After Key ATTR-CM And LGMD2I/R9 Milestones

Simply Wall St.

BridgeBio: Advancing First-in-Class LGMD Therapy and Blockbuster ATTR Franchise Underpin Reiterated Buy and $100 Target

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

Alnylam Pharmaceuticals: Durable ATTR Growth and Amvuttra Momentum Support Buy Rating and Upside Potential

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/ATTR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ATTR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","market":"US","secType":"STK","nameCN":"Arin Tactical Tail Risk ETF","latestPrice":95.1491,"timestamp":1789070400000,"preClose":95.3184,"halted":0,"volume":2338,"hourTrading":{"tag":"盘后","latestPrice":95.1491,"preClose":95.1491,"latestTime":"16:10 EDT","volume":2,"amount":190.2982,"timestamp":1789071007286,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.001776152348339803,"floatShares":1169146,"shares":1169146,"eps":0,"marketStatus":"Post-Mkt","change":-0.1693,"latestTime":"09-10 16:27:16 EDT","open":95.17,"high":95.19,"low":95.1491,"amount":222511,"amplitude":0.000429,"askPrice":142.63,"askSize":200,"bidPrice":47.55,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":95.3184,"sharesOutstanding":989146,"nav":95.4,"aum":111536528.4,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":95.1491,"preClose":95.1491,"latestTime":"16:10 EDT","volume":2,"amount":190.2982,"timestamp":1789071007286,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.875502},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","floatShares":1169146,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.875502,"shares":1169146,"dividePrice":0,"high":95.19,"amplitude":0.000429,"preClose":95.3184,"low":95.1491,"week52Low":45.1,"pbRate":"--","week52High":95.585,"institutionHeld":0,"latestPrice":95.1491,"eps":0,"divideRate":0,"volume":2338,"delay":0,"ttmEps":0,"open":95.17,"prevYearClose":90.4492,"prevWeekClose":95.4701,"prevMonthClose":95.2648,"prevQuarterClose":93.4307,"fiveDayClose":95.214,"twentyDayClose":95.1486,"sixtyDayClose":94.1485},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATTR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATTR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATTR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATTR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653752839","title":"Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune","url":"https://stock-news.laohu8.com/highlight/detail?id=2653752839","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653752839?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:05","pubTimestamp":1784718300,"startTime":"0","endTime":"0","summary":"NEW YORK, July  22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $42","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/22/3331241/0/en/Royalty-Pharma-acquires-royalty-interest-in-AstraZeneca-s-cliramitug-for-up-to-425-million-from-Neurimmune.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650199138","title":"Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2650199138","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650199138?lang=en_us&edition=fundamental","pubTime":"2026-07-10 20:29","pubTimestamp":1783686596,"startTime":"0","endTime":"0","summary":"Why Alnylam Pharmaceuticals Stock Is Back in Focus\nAlnylam Pharmaceuticals (ALNY) moved sharply higher after a late stage trial for a competing transthyretin amyloid cardiomyopathy treatment from AstraZeneca and Ionis Pharmaceuticals failed, shifting investor attention toward Alnylam’s ATTR portfolio.\nSee our latest analysis for Alnylam Pharmaceuticals.\nThat ATTR news lands on top of a mixed year for Alnylam Pharmaceuticals, with the share price at $312.79, a year to date share price decline...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-28-undervalued-followi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-28-undervalued-followi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PBE","BK4588","LU0882574055.USD","LU0320765992.SGD","ATTR","LU0114720955.EUR","LU0109394709.USD","ALNY","BK4548","LU0889565916.HKD","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504160","title":"Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504160","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648504160?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:30","pubTimestamp":1782991800,"startTime":"0","endTime":"0","summary":"- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/02/3321249/0/en/Acoramidis-Associated-with-First-Ever-Early-and-Sustained-Direct-Kidney-Protective-Effects-in-ATTR-CM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","ATTR","BK4081","CM","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642406644","title":"DKSH Partners with BridgeBio to Distribute ATTR-CM Drug in Key Asia-Pacific Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2642406644","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642406644?lang=en_us&edition=fundamental","pubTime":"2026-06-11 13:33","pubTimestamp":1781156020,"startTime":"0","endTime":"0","summary":"An update from DKSH Holding AG ( ($CH:DKSH) ) is now available. DKSH’s Healthcare unit has entered a strategic distribution partnership with U.S. b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dksh-partners-with-bridgebio-to-distribute-attr-cm-drug-in-key-asia-pacific-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dksh-partners-with-bridgebio-to-distribute-attr-cm-drug-in-key-asia-pacific-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","CM","BK4581","BK4585","ATTR","BK4207","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642420113","title":"AstraZeneca Advances Dual ATTR-CM Therapy With New Phase IIb Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642420113","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642420113?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:33","pubTimestamp":1781109232,"startTime":"0","endTime":"0","summary":"AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca has launched a new mid‑stage study in heart disease tied...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astrazeneca-advances-dual-attr-cm-therapy-with-new-phase-iib-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astrazeneca-advances-dual-attr-cm-therapy-with-new-phase-iib-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATTR","BK4207","CM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634821492","title":"Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2634821492","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634821492?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:30","pubTimestamp":1778506200,"startTime":"0","endTime":"0","summary":"-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated prof","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291995/0/en/Acoramidis-Continues-to-Demonstrate-Disease-Modifying-Effects-in-ATTR-CM-Reducing-sTTR-Variability-and-Outpatient-Worsening-Heart-Failure.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1939255532.USD","LU1861214812.USD","BK4207","LU2244417387.USD","BK4516","LU2360107325.USD","LU2238339852.HKD","LU2298064838.USD","ACM","BK4129","LU0689626769.HKD","BK4081","EMA","LU1861219969.SGD","LU0124676726.USD","ATTR","LU2308191902.HKD","LU0187121727.USD","CM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633180927","title":"BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=2633180927","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633180927?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:30","pubTimestamp":1778067000,"startTime":"0","endTime":"0","summary":"- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288693/0/en/BEYONTTRA-acoramidis-the-First-Near-Complete-TTR-Stabilizer-90-Approved-by-ANVISA-to-Treat-ATTR-CM-in-Brazil.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","ATTR","EWZS","CM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627423514","title":"AstraZeneca Targets Early Detection in China With New ATTR Heart Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2627423514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627423514?lang=en_us&edition=fundamental","pubTime":"2026-04-15 00:30","pubTimestamp":1776184258,"startTime":"0","endTime":"0","summary":"AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The AstraZeneca study “A Prospective, Multicenter, Intervention Stud...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astrazeneca-targets-early-detection-in-china-with-new-attr-heart-disease-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astrazeneca-targets-early-detection-in-china-with-new-attr-heart-disease-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627743564","title":"Assessing BridgeBio Pharma (BBIO) Valuation After Key ATTR-CM And LGMD2I/R9 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2627743564","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627743564?lang=en_us&edition=fundamental","pubTime":"2026-04-13 16:17","pubTimestamp":1776068253,"startTime":"0","endTime":"0","summary":"Why BridgeBio Pharma is back on investor radars\nBridgeBio Pharma (BBIO) has drawn fresh attention after releasing long-term data for its ATTR-CM drug acoramidis and filing an FDA New Drug Application for BBP-418 in limb-girdle muscular dystrophy.\nThese product updates, together with new analyst coverage highlighting BridgeBio's broader rare disease pipeline, have refocused the market on how its existing approvals and late-stage programs might shape the company’s future profile.\nSee our latest...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/assessing-bridgebio-pharma-bbio-valuation-after-key-attr-cm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/assessing-bridgebio-pharma-bbio-valuation-after-key-attr-cm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","ATTR","BK4588","CM","BK4139","BK4207","BBIO","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623588146","title":"BridgeBio: Advancing First-in-Class LGMD Therapy and Blockbuster ATTR Franchise Underpin Reiterated Buy and $100 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2623588146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623588146?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:37","pubTimestamp":1774953446,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterate...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bridgebio-advancing-first-in-class-lgmd-therapy-and-blockbuster-attr-franchise-underpin-reiterated-buy-and-100-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bridgebio-advancing-first-in-class-lgmd-therapy-and-blockbuster-attr-franchise-underpin-reiterated-buy-and-100-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4581","XLV","ATTR","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623329341","title":"Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54","url":"https://stock-news.laohu8.com/highlight/detail?id=2623329341","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623329341?lang=en_us&edition=fundamental","pubTime":"2026-03-31 03:30","pubTimestamp":1774899000,"startTime":"0","endTime":"0","summary":"- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) - Acoramidis mitigated the rise in NT-proBNP through Month ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264934/0/en/Acoramidis-Significantly-Reduces-the-Risk-of-All-Cause-and-Cardiovascular-Mortality-in-Patients-with-ATTR-CM-through-Month-54.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACM","LU1939255532.USD","LU1861214812.USD","BK4081","LU2308191902.HKD","CM","LU0124676726.USD","CVM","LU2244417387.USD","LU0689626769.HKD","LU2298064838.USD","CSII","BK4139","ATTR","BK4129","LU1861219969.SGD","EMA","LU2360107325.USD","LU0187121727.USD","LU2238339852.HKD","BK4207","BK4082","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622219570","title":"Alnylam Pharmaceuticals: Durable ATTR Growth and Amvuttra Momentum Support Buy Rating and Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2622219570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622219570?lang=en_us&edition=fundamental","pubTime":"2026-03-25 17:35","pubTimestamp":1774431343,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on ALNY stock, giving a Buy rating today. Tazeen Ahmad has give...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alnylam-pharmaceuticals-durable-attr-growth-and-amvuttra-momentum-support-buy-rating-and-upside-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alnylam-pharmaceuticals-durable-attr-growth-and-amvuttra-momentum-support-buy-rating-and-upside-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATTR","ALNY"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":32,"code":"91000000","status":"200"}]}}